Iduronate 2-sulfatase (DrugBank: Iduronate 2-sulfatase)
1 diseaseID | Disease name (Link within this page) | Number of trials |
---|---|---|
19 | Lysosomal storage disease | 1 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT02262338 (ClinicalTrials.gov) | April 2015 | 2/10/2014 | Safety and Dose Ranging Study of Insulin Receptor MoAb-IDS Fusion Protein in Patients With Hunter Syndrome | A Phase 1 Safety and Dose-Finding Study of a Human Insulin Receptor Monoclonal Antibody-Human Iduronate 2-Sulfatase (IDS) Fusion Protein, AGT-182 in Adult Patients With Mucopolysaccharidosis II (MPS II, Hunter Syndrome) | Mucopolysaccharidosis II | Drug: AGT-182 | ArmaGen, Inc | NULL | Completed | 18 Years | N/A | Male | 6 | Phase 1 | United States;Germany;Philippines;Netherlands |